OTLK
Outlook Therapeutics (OTLK)
$15
About Outlook Therapeutics (OTLK)
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Details
Daily high
$5.23
Daily low
$4.94
Price at open
$4.94
52 Week High
$18.00
52 Week Low
$4.61
Market cap
121.8M
Dividend yield
0.00%
Volume
264,864
Avg. volume
279,937
P/E ratio
-.48
Outlook Therapeutics News
Details
Daily high
$5.23
Daily low
$4.94
Price at open
$4.94
52 Week High
$18.00
52 Week Low
$4.61
Market cap
121.8M
Dividend yield
0.00%
Volume
264,864
Avg. volume
279,937
P/E ratio
-.48